FibroTest-ActiTest is the non-invasive liver test benchmark. Launched more then 10 years ago FibroTest success relies on the quality of its scientific background. Consecutively, SteatoTest, NashTest and AshTest were finalized with the same demanding quality.
BioPredictive offers with this site the exhaustivity of its extensive scientific work - 371 studies have been published by 1584 authors in 127 journals - all publications are tagged for an easy browsing.
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
Munteanu M, Pais R, Peta V, Deckmyn O, Moussalli J, Ngo Y, Rudler M, Lebray P, Charlotte F, Thibault V, Lucidarme O, Ngo A, Imbert-Bismut F, Housset C, Thabut D, Ratziu V, Poynard T
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
Bril F, McPhaul MJ, Caulfield MP, Castille JM, Poynard T, Soldevila-Pico C, Clark VC, Firpi-Morell RJ, Lai J, Cusi K
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
Köksal İ, Yılmaz G, Parlak M, Demirdal T, Kınıklı S, Candan M, Kaya A, Akhan S, Aydogdu O, Turgut H, Gürbüz Y, Dağlı Ö, Gökal AA, Güner R, Kuruüzüm Z, Tarakçı H, Beslen N, Erdoğan S, Özdener F, Study Group TCHC
Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.
Wilson TG, d'Udekem Y, Winlaw DS, Cordina RL, Celermajer DS, Wheaton GR, Bullock A, Gentles TL, Weintraub RG, Justo RN, Grigg LE, Radford DJ, Hardikar W, Cheung M, Cain TM, Rao P, Alexander SI, Ayer J, Verrall C, Du Plessis K, Chapman J, Rice K, Barry J, Zannino D, Iyengar AJ
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS, Bzowej NH, Wong JB
Glycogenic hepatopathy.
Khoury J, Zohar Y, Shehadeh N, Saadi T
Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
Akuta N, Toyota J, Karino Y, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, McPhee F, Noviello S, Kumada H
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.
Poynard T, Munteanu M, Charlotte F, Perazzo H, Ngo Y, Deckmyn O, Pais R, Merrouche W, De Lédinghen V, Mathurin P, Ratziu V
Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.
Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
Sberna AL, Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, Duvillard L, Denimal D, Loffroy R, Verges B, Hillon P, Petit JM
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
Preda CM, Popescu CP, Baicus C, Voiosu TA, Manuc M, Pop CS, Gheorghe L, Sporea I, Trifan A, Tantau M, Tantau A, Ceausu E, Proca D, Constantinescu I, Ruta SM, Diculescu MM, Oproiu A
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Gane EJ, Feld JJ, Mangia A
Diagnostic accuracy of the Coopscore<sup>©</sup> to predict liver fibrosis in human immunodeficiency virus/hepatitis B virus co-infection.
Taibi L, Boyd A, Bosselut N, Bottero J, Guéchot J, Lacombe K, Lasnier E, Baudin B, Vaubourdolle M
Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.
Peta V, Tse C, Perazzo H, Munteanu M, Ngo Y, Ngo A, Ramanujam N, Verglas L, Mallet M, Ratziu V, Thabut D, Rudler M, Thibault V, Schuppe-Koistinen I, Bonnefont-Rousselot D, Hainque B, Imbert-Bismut F, Merz M, Kullak-Ublick G, Andrade R, van Boemmel F, Schott E, Poynard T
Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest - comparison with histopathological assessment.
Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, Pluta M, Marczyńska M
Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.
Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases.
Ducancelle A, Leroy V, Vergniol J, Sturm N, Le Bail B, Zarski JP, Nguyen Khac E, Salmon D, De Lédinghen V, Calès P
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.
Viglino D, Jullian-Desayes I, Minoves M, Aron-Wisnewsky J, Leroy V, Zarski JP, Tamisier R, Joyeux-Faure M, Pepin JL
Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.
Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.
Natarajan Y, White DL, El-Serag HB, Ramsey D, Richardson P, Kuzniarek J, Shukla R, Tansel A, Kanwal F
Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.
Kucharska M, Zaleska-Dorobisz U, Szymczak A, Inglot M, Rymer W, Zalewska M, Małyszczak K, Kuliszkiewicz-Janus M, Inglot M
Late presentation of chronic viral hepatitis for medical care: a consensus definition.
Mauss S, Pol S, Buti M, Duffell E, Gore C, Lazarus JV, der Grient HL, Lundgren J, Mozalevskis A, Raben D, Schatz E, Wiktor S, Rockstroh JK
HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
Steininger K, Boyd A, Dupke S, Krznaric I, Carganico A, Munteanu M, Neifer S, Schuetze M, Obermeier M, Arasteh K, Baumgarten A, Ingiliz P
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
Screening studies of transient elastography and FibroTest in the general population - Authors' reply.
Ginès P, Graupera I, Lammert F, Angeli P, Caballeria L, Krag A, Guha IN, Murad SD, Castéra L
Screening studies of transient elastography and FibroTest in the general population.
Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.
Fidai A, Dallaire F, Alvarez N, Balon Y, Clegg R, Connelly M, Dicke F, Fruitman D, Harder J, Myers K, Patton DJ, Prieur T, Vorhies E, Myers RP, Martin SR, Greenway SC
Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.
Poinsot P, Collardeau Frachon S, Restier L, Sérusclat A, Di Filippo M, Charrière S, Moulin P, Lachaux A, Peretti N
Transient elastography alone and in combination with FibroTest<sup>®</sup> for the diagnosis of hepatic fibrosis in alcoholic liver disease.
Voican CS, Louvet A, Trabut JB, Njiké-Nakseu M, Dharancy S, Sanchez A, Corouge M, Lamouri K, Lebrun A, Balian A, Prévot S, Lachgar M, Maitre S, Agostini H, Mathurin P, Perlemuter G, Naveau S
Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
Boyd A, Bottero J, Miailhes P, Lascoux-Combe C, Rougier H, Girard PM, Serfaty L, Lacombe K
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.
Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.
Wu FM, Earing MG, Aboulhosn JA, Johncilla ME, Singh MN, Odze RD, Ukomadu C, Gauvreau K, Landzberg MJ, Valente AM
The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.
Simental-Mendía LE, Simental-Mendía E, Rodríguez-Hernández H, Rodríguez-Morán M, Guerrero-Romero F
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.
Poynard T, Pham T, Perazzo H, Munteanu M, Luckina E, Elaribi D, Ngo Y, Bonyhay L, Seurat N, Legroux M, Ngo A, Deckmyn O, Thabut D, Ratziu V, Lucidarme O
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C, Dufour JF, Bellentani S, Ngo Y, Traussnig S, Perazzo H, Deckmyn O, Bedossa P, Ratziu V, Poynard T
Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.
Acoustic Radiation Force Impulse Imaging for Diagnosis and Monitoring of Liver Fibrosis in Patients with Hepatitis C: A Review of Diagnostic Accuracy, Clinical Effectiveness, Cost-Effectiveness, and Guidelines
[Hepatitis B virus genotypes and evolutionary markers in chronic HBsAG patients in Bujumbura].
Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, Michalak S, Chermak F, Bertrais S, Foucher J, Oberti F, Charbonnier M, Fouchard-Hubert I, Rousselet MC, Calès P, De Lédinghen V
Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.
Patel K, Tillmann HL, Matta B, Sheridan MJ, Gardner SD, Shackel NA, McHutchison JG, Goodman ZD
Usefulness of acoustic radiation force impulse and fibrotest in liver fibrosis assessment after liver transplant.
Bignulin S, Falleti E, Cmet S, Cappello D, Cussigh A, Lenisa I, Dissegna D, Pugliese F, Vivarelli C, Fabris C, Fabris C, Toniutto P
Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.
Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.
Jullian-Desayes I, Tamisier R, Zarski JP, Aron-Wisnewsky J, Launois-Rollinat SH, Trocme C, Levy P, Joyeux-Faure M, Pepin JL
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.
The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.
The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.
Gruszewska E, Gudowska M, Wójtowicz E, Cylwik B, Szmitkowski M, Chrostek L
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
Poynard T, Deckmyn O, Munteanu M, Ngo Y, Drane F, Castille JM, Housset C, Ratziu V
Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.
[Diagnostic value of FibroTest for liver fibrosis in patients with chronic hepatitis B].
Personalized management of cirrhosis by non-invasive tests of liver fibrosis.
Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.
Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review.
Kucharska M, Inglot M, Kuliszkiewicz-Janus M, Pazgan-Simon M, Knysz B
Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.
Schmid P, Bregenzer A, Huber M, Rauch A, Jochum W, Müllhaupt B, Vernazza P, Opravil M, Weber R
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
Rudler M, Mouri S, Charlotte F, Cluzel P, Ngo Y, Munteanu M, Lebray P, Ratziu V, Thabut D, Poynard T
Noninvasive Assessment of Liver Fibrosis.
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.
Fernandez M, Trepo E, Degré D, Gustot T, Verset L, Demetter P, Devière J, Adler M, Moreno C
Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.
Traoré F, Gormally E, Villar S, Friesen MD, Groopman JD, Vernet G, Diallo S, Hainaut P, Maiga MY
Study of FibroTest and hyaluronic acid biological variation in healthy volunteers and comparison of serum hyaluronic acid biological variation between chronic liver diseases of different etiology and fibrotic stage using confidence intervals.
Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.
Yakoob R, Bozom IA, Thandassery RB, Rahman MO, Derbala MF, Mohannadi MJ, John AK, Sharma M, Wani H, Kaabi SA
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
Khalaf N, White D, Kanwal F, Ramsey D, Mittal S, Tavakoli-Tabasi S, Kuzniarek J, El-Serag HB
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
Giannini EG, Afdhal NH, Sigal SH, Muir AJ, Reddy KR, Vijayaraghavan S, Elkashab M, Romero-Gómez M, Dusheiko GM, Iyengar M, Vasey SY, Campbell FM, Theodore D
[SWE elastography in assessment of liver fibrosis].
Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.
Liver fibrosis in adults with Fontan palliation: Do common screening studies predict disease severity?
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
Pais R, Rusu E, Zilisteanu D, Circiumaru A, Micu L, Voiculescu M, Poynard T, Ratziu V
Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.
Zelber-Sagi S, Salomone F, Webb M, Lotan R, Yeshua H, Halpern Z, Santo E, Oren R, Shibolet O
Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.
Park MS, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Shin SH, Kang W, Moon C, Han KH
Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.
Park MS, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Shin SH, Kang W, Moon C, Han KH
Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.
Bonnard P, Elsharkawy A, Zalata K, Delarocque-Astagneau E, Biard L, Le Fouler L, Hassan AB, Abdel-Hamid M, El-Daly M, Gamal ME, El Kassas M, Bedossa P, Carrat F, Fontanet A, Esmat G
Retracted: Executive functions in chronic hepatitis C virus infected elderly patients.
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
Perazzo H, Munteanu M, Ngo Y, Lebray P, Seurat N, Rutka F, Couteau M, Jacqueminet S, Giral P, Monneret D, Imbert-Bismut F, Ratziu V, Hartemann-Huertier A, Housset C, Poynard T
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
Poynard T, Vergniol J, Ngo Y, Foucher J, Thibault V, Munteanu M, Merrouche W, Lebray P, Rudler M, Deckmyn O, Perazzo H, Thabut D, Ratziu V, De Lédinghen V
Liver fibrosis markers in alcoholic liver disease.
[The value of noninvasive serological markers in hepatitis B].
Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
Poynard T, Vergniol J, Ngo Y, Foucher J, Thibault V, Munteanu M, Merrouche W, Lebray P, Rudler M, Deckmyn O, Perazzo H, Thabut D, Ratziu V, De Lédinghen V
FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.
Zeremski M, Dimova RB, Benjamin S, Makeyeva J, Yantiss RK, Gambarin-Gelwan M, Talal AH
The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.
Lynch M, Higgins E, McCormick PA, Kirby B, Nolan N, Rogers S, Lally A, Vellinga A, Omar H, Collins P
The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy.
[Biomarkers for liver fibrosis: advances, advantages and disadvantages.]
Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.
Boursier J, Brochard C, Bertrais S, Michalak S, Gallois Y, Fouchard-Hubert I, Oberti F, Rousselet MC, Calès P
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
Perazzo H, Pais R, Munteanu M, Ngo Y, Monneret D, Imbert-Bismut F, Moussalli J, Lebray P, Benhamou Y, Thabut D, Ratziu V, de Ledhingen V, Poynard T
Spleen stiffness measurement by transient elastography to diagnose portal hypertension in children.
FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.
Spleen stiffness measurement by transient elastography to diagnose portal hypertension in children.
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?
Non-invasive diagnosis of hepatitis B virus-related cirrhosis.
Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
Naveau S, Essoh BM, Ghinoiu M, Marthey L, Njiké-Nakseu M, Balian A, Lachgar M, Prévot S, Perlemuter G
FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
Sebastiani G, Ghali P, Wong P, Klein MB, Deschenes M, Myers RP
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
Sebastiani G, Ghali P, Wong P, Klein MB, Deschenes M, Myers RP
Hepatitis B: are non-invasive markers of liver fibrosis reliable?
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
Poynard T, Vergniol J, Ngo Y, Foucher J, Munteanu M, Merrouche W, Colombo M, Thibault V, Schiff E, Brass CA, Albrecht JK, Rudler M, Deckmyn O, Lebray P, Thabut D, Ratziu V, De Lédinghen V
Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.
Minville C, Hilleret MN, Tamisier R, Aron-Wisnewsky J, Clement K, Trocme C, Borel JC, Levy P, Zarski JP, Pepin JL
[Prognosis assessment of alcoholic liver disease: how and why?].
Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.
Castéra L, Winnock M, Pambrun E, Paradis V, Perez P, Loko MA, Asselineau J, Dabis F, Degos F, Salmon D
Evaluation of liver stiffness measurement by fibroscan as compared to liver biopsy for assessment of hepatic fibrosis in children with chronic hepatitis C.
Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.
Cassinotto C, Lapuyade B, Aït-Ali A, Vergniol J, Gaye D, Foucher J, Bailacq-Auder C, Chermak F, Le Bail B, De Lédinghen V
Silymarin in non alcoholic fatty liver disease.
Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F
[The diagnostic value of non-invasive biochemical biomarkers in alcohol abuse].
Supronowicz Ł, Wójtowicz E, Cylwik B, Gruszewska E, Chrostek L
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, Razavi H, Castéra L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM
Noninvasive evaluation of NAFLD.
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.
Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.
Calin R, Guiguet M, Desire N, Imbert-Bismut F, Munteanu M, Poynard T, Valantin MA, Stitou H, Katlama C, Thibault V
Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.
Sagrini E, Ardoino I, Marano G, Gianstefani A, Orlandini A, Sebastiani G, Donati G, Cucchetti A, Pelosi G, Ferrari C, Alberti A, Biganzoli E, Piscaglia F, Bolondi L
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, Ngo Y, Thibault V, Mkada H, Charlotte F, Bismut FI, Deckmyn O, Benhamou Y, Valantin MA, Ratziu V, Katlama C
Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis.
Friedrich-Rust M, Schlueter N, Smaczny C, Eickmeier O, Rosewich M, Feifel K, Herrmann E, Poynard T, Gleiber W, Lais C, Zielen S, Wagner TO, Zeuzem S, Bojunga J
Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.
Zarski JP, Sturm N, Guéchot J, Zafrani ES, Vaubourdolle M, Thoret S, Margier J, David-Tchouda S, Bosson JL
Commentary: prognostication of chronic hepatitis B - are Fibrotest and Fibroscan the final answers? Authors' reply.
Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.
Zarski JP, Sturm N, Guéchot J, Zafrani ES, Vaubourdolle M, Thoret S, Margier J, David-Tchouda S, Bosson JL
Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.
De Lédinghen V, Vergniol J, Barthe C, Foucher J, Chermak F, Le Bail B, Merrouche W, Bernard PH
Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.
Fouad A, Sabry D, Ahmed R, Kamal M, Allah SA, Marzouk S, Amin M, Abd El Aziz R, El Badri A, Khattab H, Helmy D
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.
Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.
Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A
Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.
Shlomai A, Halfon P, Goldiner I, Zelber-Sagi S, Halpern Z, Oren R, Bruck R
Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.
Poynard T, Munteanu M, Luckina E, Perazzo H, Ngo Y, Royer L, Fedchuk L, Sattonnet F, Pais R, Lebray P, Rudler M, Thabut D, Ratziu V
Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation.
Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.
Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.
Grattagliano I, Ubaldi E, Napoli L, Marulli CF, Nebiacolombo C, Cottone C, Portincasa P
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
Poynard T, Bruix J, Schiff ER, Diago M, Berg T, Moreno-Otero R, Lyra AC, Carrilho F, Griffel LH, Boparai N, Jiang R, Burroughs M, Brass CA, Albrecht JK
Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy.
Bosselut N, Taibi L, Guéchot J, Zarski JP, Sturm N, Gelineau MC, Poggi B, Thoret S, Lasnier E, Baudin B, Housset C, Vaubourdolle M
Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.
Chládek J, S̆imková M, Vanec̆ková J, Hroch M, Vávrová J, Hůlek P
EASL clinical practical guidelines: management of alcoholic liver disease.
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.
[The prevalence of liver and gallbladder pathologies in overweight and obese patients].
Popova IR, Pavlov ChS, Glushenkov DV, Drapkina OM, Ivashkin VT
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
De Lédinghen V, Vergniol J, Foucher J, Merrouche W, Le Bail B
Finasteride and methadone use and risk of advanced hepatitis C related liver disease.
White DL, Hashmi A, Ramsey DJ, Kuzniarek J, Tavakoli-Tabasi S, El-Serag HB
Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.
White DL, Tavakoli-Tabasi S, Kuzniarek J, Ramsey DJ, El-Serag HB
[Non-invasive evaluation of liver fibrosis in chronic hepatitis C].
Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.
Poynard T, De Lédinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Lenaour G, Vaillant JC, Ratziu V, Charlotte F
Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study.
Gangadharan B, Bapat M, Rossa J, Antrobus R, Chittenden D, Kampa B, Barnes E, Klenerman P, Dwek RA, Zitzmann N
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Castille JM, Housset C, Ratziu V, Imbert-Bismut F
Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.
Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M
Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.
Flores-Calderón J, Morán-Villota S, Ramón-García G, González-Romano B, Bojórquez-Ramos Mdel C, Cerdán-Silva L, Hernández-Frías P
Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.
Vermehren J, Vermehren A, Mueller A, Carlebach A, Lutz T, Gute P, Knecht G, Sarrazin C, Friedrich-Rust M, Forestier N, Poynard T, Zeuzem S, Herrmann E, Hofmann WP
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.
Poynard T, Lenaour G, Vaillant JC, Capron F, Munteanu M, Eyraud D, Ngo Y, M'Kada H, Ratziu V, Hannoun L, Charlotte F
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
Poynard T, Lassailly G, Diaz E, Clement K, Caiazzo R, Tordjman J, Munteanu M, Perazzo H, Demol B, Callafe R, Pattou F, Charlotte F, Bedossa P, Mathurin P, Ratziu V
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.
Zarski JP, Sturm N, Guéchot J, Paris A, Zafrani ES, Asselah T, Boisson RC, Bosson JL, Guyader D, Renversez JC, Bronowicki JP, Gelineau MC, Tran A, Trocme C, De Lédinghen V, Lasnier E, Poujol-Robert A, Ziegler F, Bourliere M, Voitot H, Larrey D, Rosenthal-Allieri MA, Fouchard Hubert I, Bailly F, Vaubourdolle M
Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.
Vermehren J, Polta A, Zimmermann O, Herrmann E, Poynard T, Hofmann WP, Bojunga J, Sarrazin C, Zeuzem S, Friedrich-Rust M
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.
White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB
Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.
De Lédinghen V, Vergniol J, Gonzalez C, Foucher J, Maury E, Chemineau L, Villars S, Gin H, Rigalleau V
Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C.
Usluer G, Erben N, Aykin N, Dagli O, Aydogdu O, Barut S, Cevik F, Ormen B
Diagnostic algorithms for liver fibrosis in hepatitis C: are they ready to avoid liver biopsy?
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.
Sebastiani G, Halfon P, Castéra L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A
Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.
Sebagh M, Samuel D, Antonini TM, Coilly A, Degli Esposti D, Roche B, Karam V, Dos Santos A, Duclos-Vallée JC, Roque-Afonso AM, Ballot E, Guettier C, Blandin F, Saliba F, Azoulay D
Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.
Boursier J, De Lédinghen V, Zarski JP, Fouchard-Hubert I, Gallois Y, Oberti F, Calès P
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
Guiu B, Crevisy-Girod E, Binquet C, Duvillard L, Masson D, Lepage C, Hamza S, Krausé D, Verges B, Minello A, Cercueil JP, Hillon P, Petit JM
Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.
Poynard T, De Lédinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Le Naour G, Vaillant JC, Ratziu V, Charlotte F
Comparison of noninvasive models of fibrosis in chronic hepatitis B.
Raftopoulos SC, George J, Bourliere M, Rossi E, de Boer WB, Jeffrey GP, Bulsara M, Speers DJ, MacQuillan G, Ching HL, Kontorinis N, Cheng W, Flexman J, Fermoyle S, Rigby P, Walsh L, McLeod D, Adams LA
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
Sebastiani G, Castéra L, Halfon P, Pol S, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A
Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.
Noninvasive assessment of portal hypertension in patients with cirrhosis.
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.
Patel K, Friedrich-Rust M, Lurie Y, Grigorescu M, Stanciu C, Lee CM, Schiff ER, Häussinger D, Manns MP, Gerken G, Colle I, Torbenson M, Pulkstenis E, Subramanian GM, McHutchison JG, Zeuzem S
Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.
Montaudié H, Sbidian E, Paul C, Maza A, Gallini A, Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, Le Maître M, Misery L, Richard MA, Ortonne JP
FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.
The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.
Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C.
Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, Rousselet MC, Zarski JP, Calès P
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
Adams LA, George J, Bugianesi E, Rossi E, de Boer WB, van der Poorten D, Ching HL, Bulsara M, Jeffrey GP
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.
Poynard T, De Lédinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Moussalli J, Lebray P, Thabut D, Ratziu V
Non-invasive markers for hepatic fibrosis.
Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.
First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.
Boursier J, De Lédinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J, Leroy V, Fouchard-Hubert I, Bertrais S, Gallois Y, Oberti F, Dib N, Calès P
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
Petit JM, Guiu B, Masson D, Duvillard L, Jooste V, Buffier P, Bouillet B, Brindisi MC, Robin I, Gambert P, Verges B, Cercueil JP, Hillon P
Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.
Stibbe KJ, Verveer C, Francke J, Hansen BE, Zondervan PE, Kuipers EJ, de Knegt RJ, van Vuuren AJ
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
Poynard T, Ngo Y, Perazzo H, Munteanu M, Lebray P, Moussalli J, Thabut D, Benhamou Y, Ratziu V
Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.
Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Messous D, Castille JM, Housset C, Ratziu V, Imbert-Bismut F
Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
Lassailly G, Caiazzo R, Hollebecque A, Buob D, Leteurtre E, Arnalsteen L, Louvet A, Pigeyre M, Raverdy V, Verkindt H, Six MF, Eberle C, Patrice A, Dharancy S, Romon M, Pattou F, Mathurin P
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
Vergniol J, Foucher J, Terrebonne E, Bernard PH, Le Bail B, Merrouche W, Couzigou P, De Lédinghen V
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.
Costa JM, Telehin D, Munteanu M, Kobryn T, Ngo Y, Thibault V, Joseph M, Ratziu V, Benhamou Y, Koz'ko V, Dubins'ka G, Poveda JD, Poynard T
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
Poynard T, Munteanu M, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Boparai N, Griffel L, Burroughs M, Brass C, Albrecht J
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
Ratziu V, De Lédinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spénard J
Performance of the FibroTest cannot be accurately estimated in nine paediatric patients with advanced fibrosis.
Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.
Castéra L, Bernard PH, Le Bail B, Foucher J, Trimoulet P, Merrouche W, Couzigou P, De Lédinghen V
Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.
Canbakan M, Senturk H, Canbakan B, Toptas T, Tabak O, Ozaras R, Tabak F, Balcı H, Sut N, Ozbay G
Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients.
Miailhes P, Pradat P, Chevallier M, Lacombe K, Bailly F, Cotte L, Trabaud MA, Boibieux A, Bottero J, Trepo C, Zoulim F
Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).
Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, Bedossa P
Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
Zarski JP, Sturm N, Desmorat H, Melin P, Raabe JJ, Bonny C, Sogni P, Pinta A, Rouanet S, Babany G, Cheveau A, Chevallier M
The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection.
Sökücü S, Gökçe S, Güllüoğlu M, Aydoğan A, Celtik C, Durmaz O
Diagnosis of fibrosis and cirrhosis. Liver biopsy is not always necessary.
Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.
Calès P, Halfon P, Batisse D, Carrat F, Perré P, Penaranda G, Guyader D, d'Alteroche L, Fouchard-Hubert I, Michelet C, Veillon P, Lambert J, Weiss L, Salmon D, Cacoub P
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.
Poynard T, Ngo Y, Munteanu M, Thabut D, Massard J, Moussalli J, Varaud A, Benhamou Y, Ratziu V
Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.
Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.
Said Y, Salem M, Mouelhi L, Mekki H, Houissa F, Ben Rejeb M, Moussa A, Trabelsi S, Debbeche R, Bouzaidi S, Najjar T
Optimization and robustness of blood tests for liver fibrosis and cirrhosis.
Calès P, Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, Dib N, Zarski JP, Rousselet MC
Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.
Laharie D, Seneschal J, Schaeverbeke T, Doutre MS, Longy-Boursier M, Pellegrin JL, Chabrun E, Villars S, Zerbib F, De Lédinghen V
Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre.
Moussalli J, Delaquaize H, Boubilley D, Lhomme JP, Merleau Ponty J, Sabot D, Kerever A, Valleur M, Poynard T
Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
Dominguez S, Ghosn J, Peytavin G, Guiguet M, Tubiana R, Valantin MA, Murphy R, Bricaire F, Benhamou Y, Katlama C
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.
Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C
ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.
Poynard T, Munteanu M, Ngo Y, Castéra L, Halfon P, Ratziu V, Imbert-Bismut F, Thabut D, Bourliere M, Cacoub P, Messous D, De Lédinghen V
Non-invasive assessment of liver fibrosis: are we ready?
Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.
El-Shabrawi MH, Mohsen NA, Sherif MM, El-Karaksy HM, Abou-Yosef H, El-Sayed HM, Riad H, Bahaa N, Isa M, El-Hennawy A
Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.
Beckebaum S, Iacob S, Klein CG, Dechêne A, Varghese J, Baba HA, Sotiropoulos GC, Paul A, Gerken G, Cicinnati VR
Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.
Bonnard P, Sombié R, Lescure FX, Bougouma A, Guiard-Schmid JB, Poynard T, Calès P, Housset C, Callard P, Le Pendeven C, Drabo J, Carrat F, Pialoux G
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
Poynard T, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, Norha P, Munteanu M, Drane F, Messous D, Bismut FI, Carrau JP, Massard J, Ratziu V, Giordanella JP
Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validation.
Munteanu M, Imbert-Bismut F, Housset C, Messous D, Fellahi S, Poynard T
Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.
Laharie D, Vergniol J, Bioulac-Sage P, Diris B, Poli J, Foucher J, Couzigou P, Drouillard J, De Lédinghen V
Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.
Castéra L, Sebastiani G, Le Bail B, De Lédinghen V, Couzigou P, Alberti A
Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.
Friedrich-Rust M, Müller C, Winckler A, Kriener S, Herrmann E, Holtmeier J, Poynard T, Vogl TJ, Zeuzem S, Hammerstingl R, Sarrazin C
Fibrotest or Fibroscan for evaluation of liver fibrosis in haemophilia patients infected with hepatitis C.
Maor Y, Halfon P, Bashari D, Penaranda G, Morali G, Klar R, Bar-Meir S, Martinowitz U, Oren R
Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection.
Hermeziu B, Messous D, Fabre M, Munteanu M, Baussan C, Bernard O, Poynard T, Jacquemin E
Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.
Anastasiou J, Alisa A, Virtue S, Portmann B, Murray-Lyon I, Williams R
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL).
Shiha G, Sarin SK, Ibrahim AE, Omata M, Kumar A, Lesmana LA, Leung N, Tozun N, Hamid S, Jafri W, Maruyama H, Bedossa P, Pinzani M, Chawla Y, Esmat G, Doss W, Elzanaty T, Sakhuja P, Nasr AM, Omar A, Wai CT, Abdallah A, Salama M, Hamed A, Yousry A, Waked I, Elsahar M, Fateen A, Mogawer S, Hamdy H, Elwakil R
Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.
Corradi F, Piscaglia F, Flori S, D'Errico-Grigioni A, Vasuri F, Tamé MR, Andreone P, Boni P, Gianstefani A, Bolondi L
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.
The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.
Mallet V, Dhalluin-Venier V, Roussin C, Bourliere M, Pettinelli ME, Giry C, Vallet-Pichard A, Fontaine H, Pol S
Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis.
Fierbinteanu-Braticevici C, Andronescu D, Usvat R, Cretoiu D, Baicus C, Marinoschi G
The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calès et al. Gastroenterol Clin Biol 2008;32:1050-60: "Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests".
An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.
Combination of fibrosis tests: sequential or synchronous?
[The scope of clinical applications of noninvasive methods for the assessment of liver fibrosis results of orginial studies in a multi-field hospital].
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.
Bottero J, Lacombe K, Guéchot J, Serfaty L, Miailhes P, Bonnard P, Wendum D, Molina JM, Lascoux-Combe C, Girard PM
Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
Halfon P, Carrat F, Bedossa P, Lambert J, Penaranda G, Perronne C, Pol S, Cacoub P
Applicability and variability of liver stiffness measurements according to probe position.
Ingiliz P, Chhay KP, Munteanu M, Lebray P, Ngo Y, Roulot D, Benhamou Y, Thabut D, Ratziu V, Poynard T
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
Rubio A, Monpoux F, Huguon E, Truchi R, Triolo V, Rosenthal-Allieri MA, Deville A, Rosenthal E, Boutté P, Tran A
The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.
Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, Le Tallec V, Oberti F, Fouchard-Hubert I, Dib N, Rousselet MC, Konaté A, Amrani N, De Lédinghen V, Calès P
Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.
Friedrich-Rust M, Schwarz A, Ong M, Dries V, Schirmacher P, Herrmann E, Samaras P, Bojunga J, Bohle RM, Zeuzem S, Sarrazin C
Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.
Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.
Liver biopsy: the best standard...when everything else fails.
Effective use of FibroTest to generate decision trees in hepatitis C.
Lau-Corona D, Pineda LA, Avilés HH, Gutiérrez-Reyes G, Farfan-Labonne BE, Núñez-Nateras R, Bonder A, Martínez-García R, Corona-Lau C, Olivera-Martínez MA, Gutiérrez-Ruiz MC, Robles-Díaz G, Kershenobich D
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.
Sebastiani G, Halfon P, Castéra L, Pol S, Thomas DL, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Guido M, Bourliere M, Noventa F, Alberti A
Changes of non-invasive markers and FibroScan values during HCV treatment.
Vergniol J, Foucher J, Castéra L, Bernard PH, Tournan R, Terrebonne E, Chanteloup E, Merrouche W, Couzigou P, De Lédinghen V
GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics.
Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, Callewaert N
Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.
Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.
Alric L, Kamar N, Bonnet D, Danjoux M, Abravanel F, Lauwers-Cances V, Rostaing L
Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C.
Boursier J, Bacq Y, Halfon P, Leroy V, De Lédinghen V, De Muret A, Bourliere M, Sturm N, Foucher J, Oberti F, Rousselet MC, Calès P
Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.
Castéra L, Le Bail B, Roudot-Thoraval F, Bernard PH, Foucher J, Merrouche W, Couzigou P, De Lédinghen V
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
Patel K, Benhamou Y, Yoshida EM, Kaita KD, Zeuzem S, Torbenson M, Pulkstenis E, Subramanian GM, McHutchison JG
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus.
Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease.
Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, Prévot S, Ngo Y, Munteanu M, Balian A, Njiké-Nakseu M, Perlemuter G, Poynard T
The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
Imbert-Bismut F, Naveau S, Morra R, Munteanu M, Ratziu V, Abella A, Messous D, Thabut D, Benhamou Y, Poynard T
Implementing non-invasive markers for liver fibrosis in clinical practice.
Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests.
Calès P, Boursier J, De Lédinghen V, Halfon P, Bacq Y, Leroy V, Dib N, Oberti F, Sawadogo A, Rousselet MC, Lunel F
Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.
Fontanges T, Bailly F, Trepo E, Chevallier M, Maynard-Muet M, Nalet B, Beorchia S, Pillon D, Moindrot H, Froissart B, Slaoui M, Tinel X, Pradat P, Trepo C
Assessment of liver fibrosis: noninvasive means.
Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V
Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.
Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, Blendis L, Halpern Z, Oren R
Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests.
Nguyen-Khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, Joly JP, Brevet M, Grignon P, Lion S, Le Page L, Dupas JL
[FibroTest-ActiTest for predicting liver fibrosis and inflammatory activity in Chinese patients with chronic hepatitis B].
Fibroscan and FibroTest/FibroMax to assess liver fibrosis/cirrhosis in patients with chronic HBV and HCV infection in Georgia.
Dolmazashvili E, Zhamutashvili M, Svanidze M, Nizharadze N, Abutidze A
FibroTest-ActiTest as a non-invasive marker of liver fibrosis.
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update.
Poynard T, Muntenau M, Morra R, Ngo Y, Imbert-Bismut F, Thabut D, Messous D, Massard J, Lebray P, Moussalli J, Benhamou Y, Ratziu V
Biomarkers of liver fibrosis.
Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.
Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load.
Ngo Y, Benhamou Y, Thibault V, Ingiliz P, Munteanu M, Lebray P, Thabut D, Morra R, Messous D, Charlotte F, Imbert-Bismut F, Bonnefont-Rousselot D, Rousselot-Bonnefont D, Moussalli J, Ratziu V, Poynard T
Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.
Munteanu M, Imbert-Bismut F, Messous D, Morra R, Thabut D, Lebray P, Benhamou Y, Ratziu V, Poynard T
Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C.
Calès P, De Lédinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, Foucher J, Bourliere M, De Muret A, Sturm N, Hunault G, Oberti F
Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients.
Bourliere M, Penaranda G, Ouzan D, Renou C, Botta-Fridlund D, Tran A, Rosenthal E, Wartelle-Bladou C, Delasalle P, Oules V, Portal I, Castellani P, Lecomte L, Rosenthal-Allieri MA, Halfon P
Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
Jacqueminet S, Lebray P, Morra R, Munteanu M, Devers L, Messous D, Bernard M, Hartemann-Heurtier A, Imbert-Bismut F, Ratziu V, Grimaldi A, Poynard T
Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection.
Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.
Friedrich-Rust M, Koch C, Rentzsch A, Sarrazin C, Schwarz P, Herrmann E, Lindinger A, Sarrazin U, Poynard T, Schäfers HJ, Zeuzem S, Abdul-Khaliq H
Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.
Cacoub P, Carrat F, Bedossa P, Lambert J, Penaranda G, Perronne C, Pol S, Halfon P
FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence.
Poynard T, Munteanu M, Ngo Y, Moussalli J, Lebray P, Thabut D, Benhamou Y, Ratziu V
Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.
The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.
Adler M, Gulbis B, Moreno C, Evrard S, Verset G, Golstein P, Frotscher B, Nagy N, Thiry P
Reproducibility of blood tests of liver fibrosis in clinical practice.
Calès P, Veillon P, Konaté A, Mathieu E, Ternisien C, Chevailler A, Godon A, Gallois Y, Joubaud F, Hubert-Fouchard I, Oberti F, Réaud S, Hunault G, Mauriat F, Lunel-Fabiani F
External validation of FibroIndex.
External validation of FibroIndex.
Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.
Rosenthal-Allieri MA, Tran A, Halfon P, Imbert-Bismut F, Munteanu M, Messous D, Peritore ML, Poynard T, Bernard A
Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?
Guidelines for the diagnosis of uncomplicated cirrhosis.
FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy.
Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.
Maor Y, Calès P, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Penaranda G, Bar-Meir S, Martinowitz U, Halfon P
Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy.
De Lédinghen V, Le Bail B, Rebouissoux L, Fournier C, Foucher J, Miette V, Castéra L, Sandrin L, Merrouche W, Lavrand F, Lamireau T
Meta-analyses of FibroTest diagnostic value in chronic liver disease.
Poynard T, Morra R, Halfon P, Castéra L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, De Lédinghen V
Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
Morali G, Maor Y, Klar R, Braun M, Ben Ari Z, Bujanover Y, Zuckerman E, Boger S, Halfon P
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.
Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, Bonino F, Brunetto MR
Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.
Morra R, Munteanu M, Bedossa P, Dargere D, Janneau JL, Paradis V, Ratziu V, Charlotte F, Thibault V, Imbert-Bismut F, Poynard T
Relationship between the Fibrotest and portal hypertension in patients with liver disease.
Thabut D, Imbert-Bismut F, Cazals-Hatem D, Messous D, Muntenau M, Valla DC, Moreau R, Poynard T, Lebrec D
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages.
Poynard T, Halfon P, Castéra L, Munteanu M, Imbert-Bismut F, Ratziu V, Benhamou Y, Bourliere M, De Lédinghen V
FibroMAX: towards a new universal biomarker of liver disease?
Morra R, Munteanu M, Imbert-Bismut F, Messous D, Ratziu V, Poynard T
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S
Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.
Berends MA, Snoek J, de Jong EM, Van Krieken JH, de Knegt RJ, van Oijen MG, van de Kerkhof PC, Drenth JP
The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.
Grigorescu M, Rusu M, Neculoiu D, Radu C, Serban A, Catanas M, Grigorescu MD
Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.
Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, Morel F, Zarski JP
Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.
Poynard T, Halfon P, Castéra L, Charlotte F, Le Bail B, Munteanu M, Messous D, Ratziu V, Benhamou Y, Bourliere M, De Lédinghen V
Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.
Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, Tran A, Botta D, Renou C, Bréchot MC, Degott C, Paradis V
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
Ratziu V, Giral P, Munteanu M, Messous D, Mercadier A, Bernard M, Morra R, Imbert-Bismut F, Bruckert E, Poynard T
FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients.
Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
Bourliere M, Penaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, Lecomte L, Castellani P, Rosenthal-Allieri MA, Gerolami R, Ouzan D, Deydier R, Degott C, Halfon P
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.
Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, De Lédinghen V
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.
Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, Lebray P, Thibault V, Benhamou Y, Moussalli J, Ratziu V, Poynard T
Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?
Maor Y, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Penaranda G, Bar-Meir S, Martinowitz U, Halfon P
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
Thabut D, Le Calvez S, Thibault V, Massard J, Munteanu M, Di Martino V, Ratziu V, Poynard T
Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.
Sène D, Limal N, Messous D, Ghillani-Dalbin P, Charlotte F, Thiollière JM, Piette JC, Imbert-Bismut F, Halfon P, Poynard T, Cacoub P
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.
Thabut D, Naveau S, Charlotte F, Massard J, Ratziu V, Imbert-Bismut F, Cazals-Hatem D, Abella A, Messous D, Beuzen F, Munteanu M, Taieb J, Moreau R, Lebrec D, Poynard T
Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.
Thabut D, Trabut JB, Massard J, Rudler M, Muntenau M, Messous D, Poynard T
Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to Fibrotest and Actitest scores.
Férard G, Piton A, Messous D, Imbert-Bismut F, Frairi A, Poynard T, Lessinger JM
Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.
Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A, Portal I, Allemand I, Bertrand JJ, Rosenthal-Allieri A, Rotily M, Sattonet C, Benderitter T, Saint Paul MC, Bonnot HP, Penaranda G, Degott C, Masseyeff MF, Ouzan D
Diagnostic value of FibroTest with normal serum aminotransferases.
Poynard T, Munteanu M, Ngo Y, Torres M, Benhamou Y, Thabut D, Ratziu V
FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases.
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, De Lédinghen V, Poynard T
A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.
d'Arondel C, Munteanu M, Moussalli J, Thibault V, Naveau S, Simon A, Messous D, Morra R, Blot C, Poynard T
Analytical variability of the Fibrotest proteins.
Rosenthal-Allieri MA, Peritore ML, Tran A, Halfon P, Benzaken S, Bernard A
Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus.
Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, Imbertbismuth F, Lebray P, Pol S
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis.
Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, Abella A, Massard J, Ngo Y, Munteanu M, Mercadier A, Manns M, Albrecht J
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.
Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, Pirisi M
A novel panel of blood markers to assess the degree of liver fibrosis.
Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
[Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test].
Piton A, Messous D, Imbert-Bismut F, Bergès J, Munteanu M, Poynard T, Hainque B
[Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of fibrotest and Actitest].
Imbert-Bismut F, Messous D, Raoult A, Poynard T, Bertrand JJ, Marie PA, Louis V, Audy C, Thouy JM, Hainque B, Piton A
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.
Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, Landais P, El Hasnaoui A, Slama A, Blin P, Thibault V, Parvaz P, Munteanu M, Trepo C
FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.
Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.
Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M, Chaput JC, Poynard T
A reference material for traceability of aspartate aminotransferase (AST) results.
Férard G, Imbert-Bismut F, Messous D, Piton A, Ueda S, Poynard T, Lessinger JM
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.
Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B
Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).
Munteanu M, Messous D, Thabut D, Imbert-Bismut F, Jouys M, Massard J, Piton A, Bonyhay L, Ratziu V, Hainque B, Poynard T
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.
Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, Messous D, Thibault V, Benhamou Y, Moussalli J, Ratziu V
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.
Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.
Imbert-Bismut F, Messous D, Thibault V, Thibaut V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mercadier A, Poynard T
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.
Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, Poynard T
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
Noninvasive prediction of fibrosis in patients with chronic hepatitis C.
Thabut D, Simon M, Myers RP, Messous D, Thibault V, Imbert-Bismut F, Poynard T
Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.
Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, Ratziu V, Bricaire F, Katlama C, Poynard T
Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.
Myers RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.
Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, Delaporte G, Doutheau D, Klump T, Sala M, Thibaud D, Trepo E, Thabut D, Myers RP, Poynard T
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.
Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.
Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.
Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.
Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest.
